ERBB2 and neoplasm: However, when adjusting for variables including tumor size, number of positive nodes, ER/PR status, and treatment, patients with HER2-low status had worse disease-free survival than those with HER2-negative tumors (hazard ratio 2.0, 95% confidence interval 1.0–4.1, p  =  0.05) [111].